VectorBuilder, a global leader in end-to-end gene delivery services, and Sartorius, a leading international partner in life science research and the biopharmaceutical industry, have recently announced a strategic cooperation agreement.

The collaboration will focus on gene vector and mRNA bioprocess solutions and services, accelerating the development and clinical translation of innovative biopharmaceutical projects.

Building on years of successful collaboration, Sartorius and the VectorBuilder have agreed to further expand the scope of their partnership. The new cooperation will cover various areas, such as co-development of innovative downstream processes for cell and gene therapies; further optimisation of the development platform and commercial production of GMP-compliant mRNA, plasmid and viral vectors; partnering to support the achievement of sustainability goals; and regular exchange as well as training of talent from both companies. Moreover, VectorBuilder will be a developing partner for applications in the field of the new modalities.

Sarah Wang, Head of Sartorius China said, "We anticipate that this strategic partnership will yield innovative solutions aimed at enhancing the efficiency and quality of biomedical enterprises. Together, we aim to support the growth of our global customers and the broader biomedical industry, and to contribute to the advancement of life sciences through transformative processes."

"Innovation is in the DNA of VectorBuilder. This agreement with Sartorius allows us to further expand our reach and impact, empowering researchers and pharmaceutical companies worldwide with advanced gene delivery solutions," said Dr Bruce Lahn, Founder and Chief Scientist of VectorBuilder.